FDA | Myeloma Trials

FDA Announcements

FDA Approved for RRMM: Sarclisa (isatuximab-irfc) + Kyprolis (Carfilzomib) and Dexamethasone (IKd)

On March 31, 2021, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, sanofi-aventis U.S. LLC) in combination with...

FDA Announcements

RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) & Dexamethasone

FDA approved for RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) and Dexamethasone Relapsed &...

FDA Announcements

FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj(Darzalex Faspro) + Kyprolis & Dexamethasone

FDA Approved for RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Kyprolis & Dexamethasone FDA approves Darzalex Faspro,...

FDA Announcements

Abecma: CART Cell Therapy -FDA Approves First Cell-Based Gene Therapy for Adult Patients with RRMM

For Immediate Release: March 27, 2021: The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene...

FDA Announcements

FDA Approved for RRMM: Xpovio (selinexor) tablets + Velcade (Bortezomib) and Dexamethasone

On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with...

FDA Announcements

FDA Approved for RRMM: Sarclisa (isatuximab-irfc) + Pomalyst (Pomalidomide) and Dexamethasone (IPd)

On March 2, 2020, the Food and Drug Administration approved isatuximab-irfc (SARCLISA, sanofi-aventis U.S. LLC) in combination with...